PAVMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
PAVmed Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.25−0.16 (-6.64%)
Close on Oct 19, 2026
- Market cap
- $14.11M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
-207.0%
Operating margin
-30712.7%
Net margin
564.8%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -97.6% | -42.7% | – | – | |
| Net income | -99.0% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -3589.5% | 3555.6% | 2.5% | |
| Return on assets | -542.2% | -253.7% | 1.2% | |
| Current ratio | 0.62 | – | 0.17 | |
| Interest coverage | – | -440.6× | -1038.4× | |
| Capex to revenue | – | – | 43.7% | |
| Diluted shares | 0M | 0M | 1M |
Where the cash went
Fiscal 2021 to 2025, five years combined
PAVmed generated $202.37M from operations and spent $3.34M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$202.37M
Used
$3.34M
Capital expenditure$3.34M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin564.8%
×Asset turnover0.00×
×Equity multiplier2.21×
=Return on equity, FY20252.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 564.8% | 0.00× | 2.21× | 2.5% |
| FY2024 | 1328.6% | 0.09× | -1.13× | -141.3% |
| FY2023 | -2617.3% | 0.06× | -1.37× | 202.1% |
| FY2022 | -23602.9% | 0.01× | 2.71× | -342.3% |
| FY2021 | -10069.4% | 0.01× | 1.68× | -158.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$401.00K
- Cash generatingOperating cash flow above zero-$5.21M
- Return on assets improvedROA up on the prior year120.1% → 1.3%
- Earnings backed by cashOperating cash flow above net income-$5.21M vs $401.00K
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.06 → 0.17
- No dilutionShare count did not rise2M → 1M
- Gross margin improvedGross margin up on the prior year-61.60% → -207.04%
- More efficientAsset turnover rose0.09 → 0.00